{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:50:46Z","timestamp":1792590646150,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1007\/s11906-008-0009-y","type":"journal-article","created":{"date-parts":[[2008,2,6]],"date-time":"2008-02-06T21:06:46Z","timestamp":1202332006000},"page":"39-45","source":"Crossref","is-referenced-by-count":77,"title":["Hypertension and kidney disease: A deadly connection"],"prefix":"10.1007","volume":"10","author":[{"given":"Yousri M.","family":"Barri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,2,7]]},"reference":[{"key":"9_CR1","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1161\/01.HYP.37.4.1053","volume":"37","author":"J.R. Sowers","year":"2001","unstructured":"Sowers JR, Epstein M, Frolich E: Diabetes, hypertension and cardiovascular disease: an update. Hypertension 2001, 37:1053\u20131059.","journal-title":"Hypertension"},{"key":"9_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00129784-200505010-00001","volume":"5","author":"J.G. Douglas","year":"2005","unstructured":"Douglas JG: Clinical guidelines for the treatment of hypertension in African Americans. Am J Cardiovasc Drugs 2005, 5:1\u20136.","journal-title":"Am J Cardiovasc Drugs"},{"key":"9_CR3","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","volume":"42","author":"A.V. Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206\u20131252.","journal-title":"Hypertension"},{"issue":"Suppl1","key":"9_CR4","first-page":"S1","volume":"43","author":"Kidney Disease Outcome Quality Initiative","year":"2004","unstructured":"Kidney Disease Outcome Quality Initiative (K\/DOQI): K\/Doqi Clinical Practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004, 43(Suppl 1):S1\u2013S290.","journal-title":"Am J Kidney Dis"},{"key":"9_CR5","doi-asserted-by":"crossref","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","volume":"134","author":"J.F. Mann","year":"2001","unstructured":"Mann JF, Gerstein HC, Pogue J, et al.: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of Ramipril: the HOPE randomized trial. Ann Intern Med 2001, 134:629\u2013636.","journal-title":"Ann Intern Med"},{"issue":"Suppl5","key":"9_CR6","first-page":"180","volume":"13","author":"N.B. Shulman","year":"1989","unstructured":"Shulman NB, Fold CE, Hall WD, et al.: Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 1989, 13(Suppl 5):180\u2013193.","journal-title":"Hypertension"},{"key":"9_CR7","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1001\/jama.1992.03490210067037","volume":"268","author":"W.G. Walker","year":"1992","unstructured":"Walker WG, Neaton JD, Cutler JA, et al.: Renal function change in hypertensive members of the Multiple Risk Factors Intervention Trial. Racial and treatment effects. The MRFIT Research Group. J Am Med Assoc 1992, 268:3085\u20133091.","journal-title":"J Am Med Assoc"},{"key":"9_CR8","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/0003-4819-123-10-199511150-00003","volume":"123","author":"J.C. Peterson","year":"1995","unstructured":"Peterson JC, Adler S, Burkart JM, et al.: Blood pressure control, proteinuria and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995, 123:754\u2013762.","journal-title":"Ann Intern Med"},{"key":"9_CR9","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1053\/ajkd.2000.16225","volume":"36","author":"G.L. Bakris","year":"2000","unstructured":"Bakris GL, William M, Dworkin L, et al., for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group: Preserving kidney function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000, 36:646\u2013661.","journal-title":"Am J Kidney Dis"},{"key":"9_CR10","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/01.HYP.25.4.587","volume":"25","author":"H.M. Perry Jr","year":"1995","unstructured":"Perry HM Jr, Miller JP, Fornoff JR, et al.: Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995, 25:587\u2013594.","journal-title":"Hypertension"},{"key":"9_CR11","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/archinte.163.13.1555","volume":"163","author":"G.L. Bakris","year":"2003","unstructured":"Bakris GL, Weir MR, Shanifar S, et al., for the RENAAL Study Group: Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL Study. Arch Intern Med 2003, 163:1555\u20131565.","journal-title":"Arch Intern Med"},{"key":"9_CR12","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1046\/j.1523-1755.2002.00213.x","volume":"61","author":"R.W. Shrier","year":"2002","unstructured":"Shrier RW, Estacio RO, Esler A, et al.: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002, 61:1086\u20131097.","journal-title":"Kidney Int"},{"key":"9_CR13","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa011489","volume":"345","author":"H. Parving","year":"2001","unstructured":"Parving H, Lehnert H, Rochner-Mortensen J, et al.: The effect of irbesartan in the development of diabetic nephropathyin patients with type 2 diabetes. N Engl J Med 2001, 345:570\u2013578.","journal-title":"N Engl J Med"},{"key":"9_CR14","doi-asserted-by":"crossref","first-page":"100S","DOI":"10.1016\/j.amjhyper.2004.11.017","volume":"18","author":"M.R. Weir","year":"2005","unstructured":"Weir MR: The role of combination antihypertensive therapy in the prevention and treatment of chronic kidney disease. Am J Hypertens 2005, 18:100S\u2013105S.","journal-title":"Am J Hypertens"},{"key":"9_CR15","first-page":"565","volume":"14","author":"C.Y. Hsu","year":"2003","unstructured":"Hsu CY, Lin F, Vittinghoff E, et al.: Racial difference in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol 2003, 14:565\u2013570.","journal-title":"J Am Soc Nephrol"},{"issue":"4Suppl","key":"9_CR16","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/S0197-2456(96)00081-5","volume":"17","author":"J.T. Wright Jr","year":"1996","unstructured":"Wright JT Jr, Kusek JW, Toto RD, et al.: Design and baseline characteristics of participants in the African-American Study of Kidney disease and Hypertension. Clin Trials 1996, 17(4 Suppl):3S\u201316S.","journal-title":"Clin Trials"},{"key":"9_CR17","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","volume":"330","author":"S. Klahr","year":"1994","unstructured":"Klahr S, Levy AS, Beck GJ, et al.: The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994, 330:877\u2013884.","journal-title":"N Engl J Med"},{"key":"9_CR18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0895-7061(97)00481-0","volume":"11","author":"B.I. Freedman","year":"1998","unstructured":"Freedman BI, Bowden DW, Rich SS, et al.: Genetic initiation of hypertensive and diabetic nephropathy. Am J Hypertens 1998, 11:251\u2013257.","journal-title":"Am J Hypertens"},{"key":"9_CR19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1056\/NEJMoa020549","volume":"348","author":"G. Keller","year":"2003","unstructured":"Keller G, Zimmer G, Mall G, et al.: Nephron number in patients with primary hypertension. N Engl J Med 2003, 348:101\u2013108.","journal-title":"N Engl J Med"},{"key":"9_CR20","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1046\/j.1523-1755.2003.00333.x","volume":"64","author":"R.D. Toto","year":"2003","unstructured":"Toto RD: Hypertensive nephrosclerosis in African Americans. Kidney Int 2003, 64:2331\u20132341.","journal-title":"Kidney Int"},{"issue":"Suppl1","key":"9_CR21","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.2337\/diacare.27.2007.S47","volume":"27","author":"American Diabetes Association","year":"2004","unstructured":"American Diabetes Association: Prevention or delay of type 2 diabetes. Diabetes Care 2004, 27(Suppl 1):S47\u2013S54.","journal-title":"Diabetes Care"},{"key":"9_CR22","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/bmj.304.6823.339","volume":"304","author":"S. Bjorck","year":"1992","unstructured":"Bjorck S, Mulec H, Johnson SA, et al.: Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992, 304:339\u2013343.","journal-title":"BMJ"},{"key":"9_CR23","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","volume":"334","author":"G. Mascjio","year":"1996","unstructured":"Mascjio G, Alberti O, Janin G, et al., for the Angiotensin-Converting Inhibitor Group: Effect of angiotensin converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996, 334:939\u2013945.","journal-title":"N Engl J Med"},{"key":"9_CR24","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/01.HYP.37.4.1047","volume":"37","author":"V.J. Dzau","year":"2001","unstructured":"Dzau VJ: Theodore Cooper Lecture: tissue angiotensin and the pathogenesis of vascular disease: a unifying hypothesis. Hypertension 2001, 37:1047\u20131052.","journal-title":"Hypertension"},{"key":"9_CR25","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1046\/j.1523-1755.2003.00940.x","volume":"63","author":"P. Jacobsen","year":"2003","unstructured":"Jacobsen P, Anderson S, Rossing K, et al.: Dual blockade of the renin angiotensin system versus maximal recommended dose of ACE inhibition of diabetic nephropathy. Kidney Int 2003, 63:1874\u20131880.","journal-title":"Kidney Int"},{"key":"9_CR26","first-page":"1094","volume":"63","author":"K. Rossing","year":"2002","unstructured":"Rossing K, Christensen PK, Jensen BR, et al.: Dual blockade of the rennin angiotensin in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002, 63:1094\u20131103.","journal-title":"Diabetes Care"},{"key":"9_CR27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","volume":"361","author":"N. Nakao","year":"2003","unstructured":"Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angiotensin II receptor blocker and angiotensinconverting-enzyme inhibitor in non diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003, 361:117\u2013124.","journal-title":"Lancet"},{"key":"9_CR28","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000046262","volume":"21","author":"M.V. Rocco","year":"2001","unstructured":"Rocco MV, Yan G, Heyka RJ, et al.: Risk factors for hypertension in chronic hemodialysis patients: baseline data from the HEMO study. Am J Nephrol 2001, 21:280\u2013288.","journal-title":"Am J Nephrol"},{"key":"9_CR29","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0002-9343(03)00366-8","volume":"115","author":"R. Agarwal","year":"2003","unstructured":"Agarwal R, Niesenson AR, Batlle D, et al.: Prevalence, treatment and control of hypertension in hemodialysis patients in the United States. Am J Med 2003, 115:291\u2013297.","journal-title":"Am J Med"},{"key":"9_CR30","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0272-6386(99)70188-5","volume":"33","author":"F.K. Post","year":"1999","unstructured":"Post FK, Hulbert-Shearon TE, Wolfe RA, et al.: Pre-dialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 1999, 33:507\u2013517.","journal-title":"Am J Kidney Dis"},{"key":"9_CR31","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1046\/j.1523-1755.1998.00005.x","volume":"54","author":"P.G. Zager","year":"1998","unstructured":"Zager PG, Nikolic J, Brown RH, et al.: \u201cU\u201d curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int 1998, 54:561\u2013569.","journal-title":"Kidney Int"},{"key":"9_CR32","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/ndt\/18.3.563","volume":"18","author":"M. Liu","year":"2003","unstructured":"Liu M, Takahashi H, Morita Y, et al.: Non-dipping is a potent predictor of cardiovascular mortality and is associated with autonomic dysfunction in hemodialysis patients. Nephrol Dial Transplant 2003, 18:563.","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl1","key":"9_CR33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1681\/ASN.V48s30","volume":"4","author":"M.R. First","year":"1994","unstructured":"First MR, Neylan JF, Rocher LL, et al.: Hypertension after renal transplantation. J Am Soc Nephrol 1994, 4(Suppl 1):30\u201336.","journal-title":"J Am Soc Nephrol"},{"key":"9_CR34","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0025-6196(12)65772-3","volume":"69","author":"S.C. Texter","year":"1994","unstructured":"Texter SC, Canzanello VJ, Talor SJ, et al.: Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc 1994, 69:1182\u20131193.","journal-title":"Mayo Clin Proc"},{"key":"9_CR35","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0272-6386(99)70414-2","volume":"33","author":"D.L. Veenstra","year":"1999","unstructured":"Veenstra DL, Best JH, Hornberger J, et al.: Incidence and long-term cost of steroid related side effects after renal transplantation. Am J Kidney Dis 1999, 33:829\u2013839.","journal-title":"Am J Kidney Dis"},{"key":"9_CR36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1523-1755.1998.00744.x","volume":"53","author":"G. Opelz","year":"1998","unstructured":"Opelz G, Wujciak T, Ritz E: Association of chronic kidney graft failure with recipient blood pressure. Kidney Int 1998, 53:217\u2013222.","journal-title":"Kidney Int"},{"key":"9_CR37","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/ki.1993.101","volume":"43","author":"P. Ruggenenti","year":"1993","unstructured":"Ruggenenti P, Perico N, Mosconi L, et al.: Calcium channel blockers protect transplant patients from cyclosporine induced daily renal hypoperfusion. Kidney Int 1993, 43:706\u2013711.","journal-title":"Kidney Int"},{"key":"9_CR38","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/ndt\/17.7.1166","volume":"17","author":"K. Midtvedt","year":"2002","unstructured":"Midtvedt K, Hartmann A: Hypertension after kidney transplantation: are treatment guidelines emerging. Nephrol Dial Transplant 2002, 17:1166\u20131169.","journal-title":"Nephrol Dial Transplant"},{"key":"9_CR39","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1097\/00007890-200112150-00013","volume":"72","author":"K. Midtvedt","year":"2001","unstructured":"Midtvedt K, Hartmann A, Foss A, et al.: Sustained improvement of renal graft function for 2 years in hypertensive renal transplant recipients treated with nifedipine compared to lisinopril. Transplantation 2001, 72:1787\u20131792.","journal-title":"Transplantation"},{"key":"9_CR40","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2165\/00003495-199958060-00005","volume":"58","author":"A.S. Olyaei","year":"1999","unstructured":"Olyaei AS, deMottos AM, Bennett WM: A practical guide to the management of hypertension in renal transplant recipients. Drugs 1999, 58:1011\u20131027.","journal-title":"Drugs"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-008-0009-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-008-0009-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-008-0009-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T05:53:51Z","timestamp":1708581231000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-008-0009-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["9"],"URL":"https:\/\/doi.org\/10.1007\/s11906-008-0009-y","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}